Wells Fargo
ACTU

Wells Fargo’s Actuate Therapeutics ACTU Stock Holding History

Wells Fargo’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1K Sell
5,889
-14,257
-71% -$59.1K ﹤0.01% 5847
2025
Q4 		$123K Buy
20,146
+6,604
+49% +$45.4K ﹤0.01% 5299
2025
Q3 		$90.6K Buy
13,542
+746
+6% +$5.41K ﹤0.01% 5370
2025
Q2 		$78.2K Buy
+12,796
New +$112K ﹤0.01% 5334
2024
Q4 		– Sell
-3,392
Closed -$25.3K – 7234
2024
Q3 		$25.3K Buy
+3,392
New +$26.9K ﹤0.01% 5572

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's ACTU Position: Q1 2026 in Review

Wells Fargo reduced its Actuate Therapeutics (ACTU) stake by 71% in Q1 2026, selling an estimated $59.1K and leaving 5,889 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5847.

Wells Fargo first reported a position in ACTU in Q3 2024 and has held it in 5 quarters since. The position peaked at $123K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Wells Fargo held 5,889 shares of Actuate Therapeutics worth $16.1K as of Q1 2026.
  • Wells Fargo sold 14,257 Actuate Therapeutics shares in Q1 2026, an estimated $59.1K.
  • Actuate Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5847 holding.
  • Wells Fargo first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Wells Fargo's Actuate Therapeutics position peaked at $123K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.